CA
SAGE icon

Crewe Advisors’s Sage Therapeutics SAGE Stock Holding History

Crewe Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-55
Closed -$2.31K – 984
2023
Q1 		$2.31K Hold
55
– – ﹤0.01% 710
2022
Q4 		$2.1K Hold
55
– – ﹤0.01% 830
2022
Q3 		$2K Hold
55
– – ﹤0.01% 1073
2022
Q2 		$2K Buy
+55
New +$1.84K ﹤0.01% 1006

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Crewe Advisors's SAGE Position: Q2 2023 in Review

Crewe Advisors sold out of Sage Therapeutics (SAGE) in Q2 2023, closing a stake of 55 shares — an estimated $2.31K sold.

Crewe Advisors first reported a position in SAGE in Q2 2022 and held it in 4 quarters. The position peaked at $2.31K in Q1 2023. 225 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

  • Crewe Advisors reported no remaining Sage Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 55 Sage Therapeutics shares in Q2 2023, an estimated $2.31K.
  • Crewe Advisors first reported a position in Sage Therapeutics in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's Sage Therapeutics position peaked at $2.31K in Q1 2023.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.